Technology

AcK-Lock masking module

Transforming bare agents into targeted cancer therapeutics

A versatile platform for targeted therapy named AcK-Lock. By requiring both histone deacetylase (HDAC) and cathepsin L (CTSL) activities as a selective modality, this prodrug strategy can render highly specific drug activation in a wide range of cancer cells. Addition of AcK-Lock module can generate a therapeutic window even if the original agent lacks it (see below), potentially leading to a paradigm shift in cancer drug development. 

Selective Metabolic Labeling

Setting up red flags 🚩🚩🚩 on cancer cells

PRUNUS’ core technology Selective Metabolic Labeling is uniquely positioned in the field of immuno-oncology using non-toxic small molecules that can be selectively loaded into cancer cells. It takes advantage of AcK-Locka prodrug strategy that can selectively label proteins produced in a broad spectrum of cancer cells with foreign tags. This approach can serve as a powerful tool for precision therapeutics & diagnostics.

Based on this scientifically proven technology as published in leading journals (Nature Communications, Theranostics) and patents (US9872919, WO2015021305A1), PRUNUS is now developing breakthrough therapeutic/diagnostic strategies that may dramatically improve the treatment outcome as well as quality of life by working together with the body’s immune system. Our approach is sustainable and could ultimately benefit many people's lives.